Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Inclusion Criteria: * Give their signed written informed consent to participate. * Are at least 40 years of age and no older than 80 at Visit 1. * A female of non-child bearing potential or child bearing potential, has a negative serum pregnancy test, and agrees to approved contraceptive methods. * COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society(ATS)/European Respiratory Society (ERS). * Current or former smokers with a history of at least 10 pack-years of cigarette smoking. * FEV1/FVC ratio of \<0.70. * Post-bronchodilator FEV1 must be ≥ 30% and \<80% predicted normal value calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations, and must also be greater than or equal to 750 mL. * Subject is willing and, in the opinion of the Investigator, able to adjust current COPD therapy as required by the protocol. Exclusion Criteria: * Pregnancy, nursing females or subjects trying to conceive. * Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study. * Current primary diagnosis of asthma. * History of ECG abnormalities. * Poorly controlled or worsening COPD prior to Screening or during the Screening Period. * Clinically significant bladder neck obstruction or urinary retention. * Male subjects with a trans-urethral resection of prostate (TURP) or full resection of the prostate within 6 months prior to Screening. * Cancer that has not been in complete remission for at least five years. * Inadequately treated glaucoma. * History of allergic reaction or hypersensitivity to any component of the formulations used in this study.